GlaxoSmithKline Recalls Inhalers

The devices may not contain sufficient propellant to deliver the labeled claim.

GlaxoSmithKline is voluntarily recalling their Ventolin HFA Inhalation Aerosol, 90 mcg per actuation, 200 Metered Inhalations because of a defective delivery system, according to the FDA.

Some canisters may not contain sufficient propellant to deliver the labeled claim of 200 actuations through the end of shelf life.

This is a Class II recall and impacts more than 128,000 devices.

More in Regulatory